
Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Stock Performance (90 Days)
Layoff History
Recent News
Other Biotechnology Companies
View All →Frequently Asked Questions
Has FENNEC PHARMACEUTICALS INC. had layoffs?
How many employees does FENNEC PHARMACEUTICALS INC. have?
What industry is FENNEC PHARMACEUTICALS INC. in?
Is FENNEC PHARMACEUTICALS INC. a publicly traded company?
Where is FENNEC PHARMACEUTICALS INC. headquartered?
Disclaimer
Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.
This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.
Found an error? Report it here.